BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older

CompletedOBSERVATIONAL
Enrollment

76

Participants

Timeline

Start Date

April 23, 2015

Primary Completion Date

June 14, 2019

Study Completion Date

June 14, 2019

Conditions
Ovarian Cancer
Interventions
DRUG

Bevacizumab

Bevacizumab will be prescribed by the local clinician according to the SmPC and standard of care for up to 15 months. No treatment will be provided by the Sponsor in this non-interventional study.

DRUG

Carboplatin

Carboplatin will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.

DRUG

Paclitaxel

Paclitaxel will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.

Trial Locations (26)

1000

CHU St Pierre (St Pierre), Brussels

1200

Cliniques Uni Ires Saint-Luc; Gynaecology, Brussels

2300

AZ Turnhout Sint Elisabeth, Turnhout

2610

Sint Augustinus Wilrijk, Wilrijk

2650

UZ Antwerpen, Edegem

2820

Imeldaziekenhuis, Bonheiden

2930

AZ KLINA, Brasschaat

3000

UZ Leuven Gasthuisberg, Leuven

3500

Jessa Zkh (Campus Virga Jesse), Hasselt

3600

ZOL (Sint Jan), Genk

4000

Chr de La Citadelle, Liège

CHU Sart-Tilman, Liège

Clinique Saint-Joseph, Liège

4800

CHR de Verviers - East Belgium, Verviers

5000

Clinique Ste-Elisabeth, Namur

6000

GHdC Site Notre Dame, Charleroi

7100

CH Jolimont - Lobbes (Jolimont), Haine-Saint-Paul

8000

AZ Sint Jan, Bruges

8310

AZ Sint Lucas Brugge, Assebroek

8400

AZ Damiaan, Ostend

8500

AZ Groeninge, Kortrijk

9000

AZ Maria Middelares, Ghent

AZ Sint Lucas (Sint Lucas), Ghent

UZ Gent, Ghent

9100

AZ Nikolaas (Sint Niklaas), Sint-Niklaas

9300

Onze Lieve Vrouwziekenhuis Aalst, Aalst

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02393898 - BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older | Biotech Hunter | Biotech Hunter